EU-FUNDED RESEARCH PROJECT

European vigilance network for the management of drug-resistant viruses (Virgil)

Time of action: VIRGIL started in May 2004 and is scheduled to end its contract with the EC in April 2008, supposingly being autonomous afterwards.

EU budget (funding): € 9 million

VIRGIL is a Network of Excellence that aims to integrate and coordinate the research activities of doctors and scientists from institutions across Europe who are investigating viral resistance; in particular to influenza, and hepatitis B and C.

The network gives structure to Europe’s previously fragmented research and unites experts in the field, offering coherence and coordination between more than 60 organisations from 14 European countries. In other words, VIRGIL acts like a ‘virtual institute’ on all aspects of antiviral drug resistance in Europe. It means that Europe can comprehensively address the problem of resistance at an early stage. Staying one step ahead of the virus means a greater chance of remaining in control.

For all correspondence, please use both: Scientific Coordinator, Fabien Zoulim Senior Manager, Jerome Weinbach